myFibroScan vs GHAPP ACE
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
myFibroScan
This app assists healthcare professionals in interpreting FibroScan® results for liver health management. It provides tools and scores based on clinical studies to aid in assessing liver disease and identifying at-risk patients.
- Interpretation Guide for FibroScan® results
- FibroScan® based scores for liver disease assessment
- Fast score for MASH patient risk identification
- Agile 3+ score for advanced fibrosis identification
- Agile 4 score for cirrhosis identification
- MASH Treatment Eligibility Tool
Read full descriptionHide full description
FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.
GHAPP ACE
Read full descriptionHide full description
GHAPP ACE: Your Go-To App for GI and Liver Health Education GHAPP ACE (Application for Clinical Exchange) is the ultimate medical platform designed exclusively for NPs and PAs specializing in gastroenterology and hepatology. This app brings together advanced practice providers in one place, offering a comprehensive resource to enhance your knowledge and clinical practice in treating GI and liver disorders. With GHAPP ACE, you gain access to the latest cutting-edge information from leading Advanced Practice Providers. Our app offers a wide range of educational resources, including FAQ video modules, medication reviews, podcasts, and GHAPP News. Stay informed about upcoming GHAPP events, engage with peers on the message board, and listen to relevant journal clubs in your field. You’ll also find practical tools like treatment algorithms and much more. Join GHAPP ACE today and elevate your practice with the most current and relevant information in gastroenterology and hepatology, all in one app.
Screenshots
Verdict
The clearest difference is update cadence: GHAPP ACE at fortnightly against myFibroScan's every 8 months. GHAPP ACE also leads on iOS requirement (13.0 vs 15.6). On price, ads, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
myFibroScan ships an update every 8 months, GHAPP ACE fortnightly. The most recent releases landed on September 16, 2026 and September 15, 2026 respectively.
| Parameter | myFibroScan | GHAPP ACE |
|---|---|---|
| Price | Free | Free |
| Rating | 3.0 (4 ratings) — better | — |
| Positive reviews | 0.0% of reviews | — |
| Number of ratings | 4 — better | — |
| Update frequency | Every 8 months | Fortnightly — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Ad-supported | — |
| Devices | iPhone, iPad, iPod — better | iPhone, iPod |
| Requires iOS | 15.6 | 13.0 — better |
| Further details — not scored | ||
| Size | 40 MB | 54 MB |
| Age rating | 17+ | 4+ |
| Developer | ECHOSENS | Tactical Advantage Group LLC |
In-app purchases
myFibroScan
No in-app purchases
GHAPP ACE
No in-app purchases







